Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

Early rescue intervention with daratumumab, pomalidomide and dexamethasone (DPd) in high-risk smoldering myeloma (HR-SMM) patients included in the GEM-CESAR treated with carfilzomib, lenalidomide and dexamethasone (KRd)- autologous stem cell transplantation (ASCT)-krd-rd

View Full Paper
Ask AI
Bookmark
Share

Authors

MGMarta Sonia GonzálezAOAlbert OriolRRRafael Ríos

Discussion

Loading...

Member takes

Overview

Phase II trial finds early rescue therapy with daratumumab and pomalidomide leads to high response rates in patients after biochemical progression.

Key Points

  • Early rescue intervention with daratumumab and pomalidomide achieved an 89.3% overall response rate, indicating strong efficacy after biochemical progression.
  • Of 29 treated patients, 6 had minimal residual disease negativity one year after starting therapy, supporting the intervention's potential.
  • Observational analysis across the GEM-CESAR trial detailed the efficacy of high-dose melphalan and autologous stem cell transplantation.
  • Neutropenia was the most common side effect in 73% of patients, highlighting the need for monitoring during treatment.

Cite This Study

González et al. (2025) studied this question.

synapsesocial.com/papers/69362f6e4fa91c937236e095https://doi.org/10.1182/blood-2025-371
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Deep responses and durable outcomes in patients treated with belantamab mafodotin plus pomalidomide and dexamethasone from long-term follow-up of the Phase 3 dreamm-8 study2025 · 4 citations
  2. 2Phase 1b study of cyclophosphamide, pomalidomide, dexamethasone, and daratumumab (CPD-DARA) in relapsed/refractory multiple myeloma: Safety and efficacy in a heavily pretreated population2025
  3. 3Characterization of NDMM patients treated with daratumumab, lenalidomide, bortezomib and dexamethasone who fail to achieve a VGPR or have early progression2025
  4. 4Efficacy and safety of daratumumab plus carfilzomib-based induction/consolidation/maintenance therapy with autologous stem cell transplantation in transplant-eligible ultra high-risk newly diagnosed multiple myeloma: Preliminary results2025
  5. 5Updated survival outcomes of pomalidomide/bortezomib/dexamethasone in newly diagnosed multiple myeloma with renal impairment: A prospective, open-label, multicenter, phase 2 study2025